Cheng Yuan-Shan, Kuang Li-Ping, Zhuang Chun-Lan, Jiang Jia-Dian, Shi Man
Yuan-Shan Cheng, MD, Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Guangdong, China, 515000.
Li-Ping Kuang, MD, Department of Pathology, Shantou Central Hospital, Guangdong, China, 515000.
Pak J Med Sci. 2015 Jan-Feb;31(1):121-6. doi: 10.12669/pjms.311.6409.
To explore the effects of cytotoxin-associated gene A (CagA) positive Helicobacter pylori (H. pylori or HP) infection on circulating B cells producing specific platelet glycoprotein antibodies and the association between therapeutic outcomes in primary idiopathic thrombocytopenic purpura (ITP) patients.
A total of 76 newly diagnosed primary ITP patients were included in the study which was conducted at the first affiliated hospital of Shantou University Medical college, in Shantou city China, between January 2013 and January 2014. These patients were tested for H. pylori infection by (13)C urea breath test and for anti-CagA antibody in H. pylori positive cases by enzyme-linked immunosorbent assay (ELISA) method. Anti-GPIb and anti-GPIIb/IIIa antibody-producing B cells were measured using an enzyme-linked immunospot (ELISPOT) assay in all ITP patients and 30 controls. Anti-nuclear antibody (ANA) was also detected in ITP patients.
The numbers of anti-GPIIb/IIIa antibody-producing B cells in HP+CagA+ patients were higher than in HP+CagA- or HP- patients. However, anti-GPIb antibody-producing B cells were found higher in HP- patients. Analysis of treatment outcomes showed that a therapeutic response was more likely in patients presenting anti-GPIIb/IIIa B cells, but the poor response was found to be associated with anti-GPIb B cells and ANA presences.
CagA antigen of H. pylori may induce anti-GPIIb/IIIa antibodies production by a molecular mimicry mechanism. Anti-GPIIb/IIIa and anti-GPIb antibody producing B Cells detection is useful for predicting treatment effects of primary ITP.
探讨细胞毒素相关基因A(CagA)阳性幽门螺杆菌(H. pylori或HP)感染对产生特异性血小板糖蛋白抗体的循环B细胞的影响,以及原发性免疫性血小板减少症(ITP)患者治疗结局之间的关联。
2013年1月至2014年1月在中国汕头市汕头大学医学院第一附属医院进行的这项研究共纳入76例新诊断的原发性ITP患者。通过(13)C尿素呼气试验检测这些患者的幽门螺杆菌感染情况,对于幽门螺杆菌阳性病例,采用酶联免疫吸附测定(ELISA)法检测抗CagA抗体。在所有ITP患者和30名对照中,使用酶联免疫斑点(ELISPOT)测定法测量产生抗糖蛋白Ib(GPIb)和抗糖蛋白IIb/IIIa(GPIIb/IIIa)抗体的B细胞。还在ITP患者中检测了抗核抗体(ANA)。
HP + CagA +患者中产生抗GPIIb/IIIa抗体的B细胞数量高于HP + CagA -或HP -患者。然而,在HP -患者中发现产生抗GPIb抗体的B细胞更高。治疗结局分析表明,出现抗GPIIb/IIIa B细胞的患者更可能有治疗反应,但发现反应不佳与抗GPIb B细胞和ANA的存在有关。
幽门螺杆菌的CagA抗原可能通过分子模拟机制诱导抗GPIIb/IIIa抗体的产生。检测产生抗GPIIb/IIIa和抗GPIb抗体的B细胞有助于预测原发性ITP的治疗效果。